SEARCH

SEARCH BY CITATION

References

  • 1
    Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40: 1759 67.
  • 2
    Inderlied CB, Salfinger M., Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolen RH, eds. Manual of clinical microbiology, 6th edn. Washington DC: ASM Press, 1995: 1385 404.
  • 3
    Woods GL & Witebsky FG. Susceptibility testing of Mycobacterium avium complex in clinical laboratories. Arch Pathol Lab Med 1996; 120: 436 9.
  • 4
    Burman WJ & Cohn DL. Clinical disease in human immunodeficiency virus-infected persons. In: BensonCA, KorvickJA, eds. Mycobacterium avium-complex infection. New York: Marcel Dekker, 1996: 79 108.
  • 5
    Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis 1991; 163: 1326 35.
  • 6
    Havlik JA Jr,, Horsburgh CR Jr,, Metchock B, Williams PP, Fann SA, Thompson SE III. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992; 165: 577 80.
  • 7
    Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6: 266 310.
  • 8
    Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis 1994; 18(suppl 3): S218 22.
  • 9
    American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1 25.
  • 10
    Horsburgh CR Jr Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332 8.
  • 11
    Masur H, The Public Health Service Task Force on Prophylaxis and Therapy For Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329: 898 904.
  • 12
    Woods GL. Disease due to the Mycobacterium avium complex in patients infected with human immunodeficiency virus: diagnosis and susceptibility testing. Clin Infect Dis 1994; 18(suppl 3): S227 32.
  • 13
    Young LS, Inderlied CB, Berlin OG, Gottlieb MS. Mycobacterial infections in AIDS patients with an emphasis on the Mycobacterium avium complex. Rev Infect Dis 1986; 8: 1024 33.
  • 14
    Prince DS, Peterson DD, Steiner RM et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863 8.
  • 15
    Cynamon M, Heifets L, Hooper N et al. Radiometric broth macrodilution method for determination of minimal inhibitory concentrations (MIC) with Mycobacterium avium complex isolates. Proposed Guidelines. Denver, CO: National Jewish Center for Immunology and Respiratory Medicine, 1993.
  • 16
    Inderlied CB. Antimycobacterial susceptibility testing: present practices and future trends. Eur J Clin Microbiol Infect Dis 1994; 13: 980 93.
  • 17
    Salfinger M & Wallace RJ Jr. Susceptibility testing for nontuberculous mycobacteria: should it be performed? Clin Microbiol News 1997; 19: 68 71.
  • 18
    Siddiqi SH, Heifets LB, Cynamon MH et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993; 31: 2332 8.
  • 19
    Heifets LB & Iseman MD. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med 1990; 323: 419 20.
  • 20
    Inderlied CB. Microbiology and minimum inhibitory concentration testing for Mycobacterium avium complex prophylaxis. Am J Med 1997; 102(5C): 2 10.DOI: 10.1016/s0002-9343(97)00037-5
  • 21
    Bownds SE, Kurzynski TA, Norden MA, Dufek JL, Schell RF. Rapid susceptibility testing for nontuberculosis mycobacteria using flow cytometry. J Clin Microbiol 1996; 34: 1386 90.
  • 22
    Cooksey RC, Morlock GP, Beggs M, Crawford JT. Bioluminescence method to evaluate antimicrobial agents against Mycobacterium avium. Antimicrob Agents Chemother 1995; 39: 754 6.
  • 23
    Moore AV, Kirk SM, Callister SM, Mazurek GH, Schell RF. Safe determination of susceptibility of Mycobacterium tuberculosis to antimycobacterial agents by flow cytometry. J Clin Microbiol 1999; 37: 479 83.
  • 24
    National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis. Proposed standard M24-T. Villanova, PA: National Committee for Clinical Laboratory Standards, 1995.
  • 25
    Wallace RJ Jr,, Nash DR, Steele LC, Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986; 24: 976 81.
  • 26
    Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother 1988; 32: 1131 6.
  • 27
    Kirk SM, Schell RF, Moore AM, Callister SM, Mazurek GH. Flow cytometric testing of susceptibilities of Mycobacterium tuberculosis isolates to ethambutol, isoniazid, and rifampin in 24 hours. J Clin Microbiol 1998; 36: 1568 73.
  • 28
    Norden MA, Kurzynski TA, Bownds SE, Callister SM, Schell RF. Rapid susceptibility testing of Mycobacterium tuberculosis (H37 Ra) by flow cytometry. J Clin Microbiol 1995; 33: 1231 7.
  • 29
    Schell RF, Moore AV, Vena RM, Kirk SM, Callister SM. Flow cytometric testing of susceptibilities of Mycobacterium tuberculosis. Clin Immunol News 1999; 19: 14 16.